Hideki Kamada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideki Kamada has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Keiichi Okano
Department of Gastroenterological Surgery, Faculty of Medicine Kagawa University Kita‐gun Japan
6 shared publicationsTsutomu Masaki
Department of Gastroenterology and Neurology, Faculty of Medicine Kagawa University Kita‐gun Japan
6 shared publicationsHiroki Yamana
Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan
5 shared publicationsHideki Kobara
Department of Gastroenterology and Neurology Faculty of Medicine Kagawa University Kagawa Japan
4 shared publications- Hironobu Suto
Department of Gastroenterological Surgery, Faculty of Medicine Kagawa University Kagawa Japan
3 shared publications - Keiichi Okano
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
3 shared publications
Latest Publications
- 3 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-9
Outcomes of Spiral Versus Conventional Double Pigtail Plastic Stents in Permanent Transpapillary Gallbladder Drainage for Acute Cholecystitis
Purpose Endoscopic gallbladder stenting is an important definitive treatment option for acute cholecystitis in high-risk patients who are poor surgical candidates. In this study, we aimed to compare the outcomes between a novel 5-Fr spiral-shaped plastic stent (IYO-stent) and conventional 7-Fr double-pigtail stent (C-stent) for permanent transpapillary gallbladder drainage. Methods This retrospective cohort study included 56 patients with acute cholecystitis who underwent permanent endoscopic gallbladder stenting at 2 Japanese centers between 2019 and 2023 (C-stent, n = 27; IYO-stent, n = 29). The primary endpoint was event-free survival (EFS), defined as the time to recurrent cholecystitis, procedure-related complications, stent dysfunction, complications requiring intervention, or death. The secondary endpoints were cholecystitis recurrence-free survival and technical success. Results The median EFS was 10.6 months (95% confidence interval [CI], 2.7– not available) in the C-stent group and was not reached in the IYO-stent group; the 24-month EFS rates were 41.6% (95% CI, 22.2–59.9) and 92.0% (95% CI: 71.1–98.0), respectively. The IYO-stent was associated with a lower risk of events compared to the C-stent (adjusted hazard ratio 0.17, 95% CI 0.05–0.55). Cholecystitis recurrence-free survival rates at 24 months were 58.2% with C-stents and 100% with IYO-stents. The technical success was 100% in both groups. Conclusions In high-risk patients undergoing permanent endoscopic transpapillary gallbladder drainage, the novel 5-Fr IYO-stent showed superior long-term efficacy over conventional 7-Fr double-pigtail stents, with markedly improved event-free survival and absence of cholecystitis recurrence during follow-up.
- 3 April 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-9
Outcomes of Spiral Versus Conventional Double Pigtail Plastic Stents in Permanent Transpapillary Gallbladder Drainage for Acute Cholecystitis
Purpose Endoscopic gallbladder stenting is an important definitive treatment option for acute cholecystitis in high-risk patients who are poor surgical candidates. In this study, we aimed to compare the outcomes between a novel 5-Fr spiral-shaped plastic stent (IYO-stent) and conventional 7-Fr double-pigtail stent (C-stent) for permanent transpapillary gallbladder drainage. Methods This retrospective cohort study included 56 patients with acute cholecystitis who underwent permanent endoscopic gallbladder stenting at 2 Japanese centers between 2019 and 2023 (C-stent, n = 27; IYO-stent, n = 29). The primary endpoint was event-free survival (EFS), defined as the time to recurrent cholecystitis, procedure-related complications, stent dysfunction, complications requiring intervention, or death. The secondary endpoints were cholecystitis recurrence-free survival and technical success. Results The median EFS was 10.6 months (95% confidence interval [CI], 2.7– not available) in the C-stent group and was not reached in the IYO-stent group; the 24-month EFS rates were 41.6% (95% CI, 22.2–59.9) and 92.0% (95% CI: 71.1–98.0), respectively. The IYO-stent was associated with a lower risk of events compared to the C-stent (adjusted hazard ratio 0.17, 95% CI 0.05–0.55). Cholecystitis recurrence-free survival rates at 24 months were 58.2% with C-stents and 100% with IYO-stents. The technical success was 100% in both groups. Conclusions In high-risk patients undergoing permanent endoscopic transpapillary gallbladder drainage, the novel 5-Fr IYO-stent showed superior long-term efficacy over conventional 7-Fr double-pigtail stents, with markedly improved event-free survival and absence of cholecystitis recurrence during follow-up.
- 10 March 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (6) , 404-414
Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
Background: Despite a strong association between nutritional indices and disease prognosis, evidence regarding the evaluation of nutritional indices after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC) is insufficient. We evaluated the clinical significance of the prognostic nutritional index (PNI) in patients with resectable (R‐) and borderline resectable (BR‐) PDAC who received neoadjuvant chemoradiotherapy (NACRT) followed by pancreatic resection.Methods: We assessed 153 patients with R‐ and BR‐PDAC who underwent NACRT followed by curative resection between 2009 and 2022. We evaluated the association between preoperative PNI after NACRT and short‐ and long‐term outcomes.Results: The median preoperative PNI value after NACRT was 42.1, and the optimal cutoff value from the time‐dependent receiver operating characteristic curve was 38.6. The low PNI group (PNI < 38.6, n = 44) exhibited significantly worse inflammatory parameters, surgical outcomes, and prognoses than the high PNI group (PNI ≥ 38.6, n = 109). Multivariate analysis identified preoperative PNI ≤ 38.6 (hazard ratio [HR]: 2.32, 95% confidence interval [CI]: 1.00–5.38, p = .049), blood loss ≥1642 mL (HR: 3.05, 95% CI: 1.65–5.64, p < .001), node positive pathology (HR: 2.10, 95% CI: 1.32–3.34, p = .002), and lack of postoperative adjuvant chemotherapy (HR: 3.55, 95% CI: 2.05–6.15, p < .001) as significant predictors of overall survival.Conclusions: For patients with R‐ and BR‐PDAC receiving preoperative treatment, it is imperative to closely monitor their nutritional status when determining the optimal surgical procedure timing.
- 10 March 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (6) , 404-414
Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data
Background: Despite a strong association between nutritional indices and disease prognosis, evidence regarding the evaluation of nutritional indices after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC) is insufficient. We evaluated the clinical significance of the prognostic nutritional index (PNI) in patients with resectable (R‐) and borderline resectable (BR‐) PDAC who received neoadjuvant chemoradiotherapy (NACRT) followed by pancreatic resection.Methods: We assessed 153 patients with R‐ and BR‐PDAC who underwent NACRT followed by curative resection between 2009 and 2022. We evaluated the association between preoperative PNI after NACRT and short‐ and long‐term outcomes.Results: The median preoperative PNI value after NACRT was 42.1, and the optimal cutoff value from the time‐dependent receiver operating characteristic curve was 38.6. The low PNI group (PNI < 38.6, n = 44) exhibited significantly worse inflammatory parameters, surgical outcomes, and prognoses than the high PNI group (PNI ≥ 38.6, n = 109). Multivariate analysis identified preoperative PNI ≤ 38.6 (hazard ratio [HR]: 2.32, 95% confidence interval [CI]: 1.00–5.38, p = .049), blood loss ≥1642 mL (HR: 3.05, 95% CI: 1.65–5.64, p < .001), node positive pathology (HR: 2.10, 95% CI: 1.32–3.34, p = .002), and lack of postoperative adjuvant chemotherapy (HR: 3.55, 95% CI: 2.05–6.15, p < .001) as significant predictors of overall survival.Conclusions: For patients with R‐ and BR‐PDAC receiving preoperative treatment, it is imperative to closely monitor their nutritional status when determining the optimal surgical procedure timing.
- Open Access
- 20 December 2022
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 30 (6) , 802-814
P53 immunolabeling in EUS‐FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy
Purpose: KRAS, P16, TP53, and SMAD4/DPC4 mutations are common in pancreatic ductal adenocarcinoma (PDAC). The study aimed to evaluate the association between gene mutations in pre‐treatment endoscopic ultrasound‐guided fine needle aspiration (EUS‐FNA) samples and clinical outcomes of patients with PDAC.Methods: There were 43 patients with resectable (R) PDAC and 41 patients with borderline resectable (BR) PDAC. CDKN2A/p16, TP53, and SMAD4/DPC4 were evaluated through immunohistochemistry (IHC) of pretreatment EUS‐FNA (n = 84) and resected specimens (n = 71). All patients received neoadjuvant therapy.Results: IHC of EUS‐FNA specimens revealed p16 loss in 61 (73%), abnormal p53 in 61 (73%), and Smad4 loss in 38 (45%) patients. Abnormal p53 was associated with a lower resection rate (p = .017). Abnormal p53 and Smad4 loss were associated with recurrence within 6 months post‐pancreatectomy (p = .03, p = .03, respectively). Univariate Cox regression analysis was conducted to reveal that abnormal p53 (p = .07), p16 loss and abnormal p53 (p = .04), and Smad4 and p16 loss (p = .03) were associated with poor prognosis.Conclusions: Pre‐treatment abnormal labeling of p53 in EUS‐FNA specimen was associated with a lower resection rate and an early recurrence in R or BR PDAC cases.
- 20 December 2022
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 30 (6) , 802-814
Open AccessP53 immunolabeling in EUS‐FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy
Purpose: KRAS, P16, TP53, and SMAD4/DPC4 mutations are common in pancreatic ductal adenocarcinoma (PDAC). The study aimed to evaluate the association between gene mutations in pre‐treatment endoscopic ultrasound‐guided fine needle aspiration (EUS‐FNA) samples and clinical outcomes of patients with PDAC.Methods: There were 43 patients with resectable (R) PDAC and 41 patients with borderline resectable (BR) PDAC. CDKN2A/p16, TP53, and SMAD4/DPC4 were evaluated through immunohistochemistry (IHC) of pretreatment EUS‐FNA (n = 84) and resected specimens (n = 71). All patients received neoadjuvant therapy.Results: IHC of EUS‐FNA specimens revealed p16 loss in 61 (73%), abnormal p53 in 61 (73%), and Smad4 loss in 38 (45%) patients. Abnormal p53 was associated with a lower resection rate (p = .017). Abnormal p53 and Smad4 loss were associated with recurrence within 6 months post‐pancreatectomy (p = .03, p = .03, respectively). Univariate Cox regression analysis was conducted to reveal that abnormal p53 (p = .07), p16 loss and abnormal p53 (p = .04), and Smad4 and p16 loss (p = .03) were associated with poor prognosis.Conclusions: Pre‐treatment abnormal labeling of p53 in EUS‐FNA specimen was associated with a lower resection rate and an early recurrence in R or BR PDAC cases.
- 17 May 2021
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (5) , E33-E35
Repeated balloon inflation under low pressure may reduce serious adverse events during endoscopic papillary large balloon dilation
Click on the article title to read more.
- 17 May 2021
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (5) , E33-E35
Repeated balloon inflation under low pressure may reduce serious adverse events during endoscopic papillary large balloon dilation
Click on the article title to read more.
- 28 February 2021
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 28 (10) , 856-863
Comparison of plastic stent versus metal stent in preoperative biliary drainage for pancreatic head cancer with neoadjuvant chemoradiotherapy
Background While neoadjuvant chemotherapy and chemoradiotherapy (NACRT) for pancreatic head cancer are effective, preoperative endoscopic biliary drainage (EBD) is necessary for managing obstructive jaundice and cholangitis during the preoperative waiting period. Nevertheless, ideal choice of stent type is unclear. We compared plastic stents (PS) and metal stents (MS) in these situations. Methods We retrospectively studied 43 patients who successfully underwent preoperative EBD prior to NACRT for pancreatic head cancer at a single institution. We divided patients into PS (n = 22) and MS (n = 21) groups. The primary outcome was the rate of re‐interventional drainage rate before surgery. Secondary outcomes were rates of EBD‐associated and postoperative complications and total costs in the pre‐ and perioperative periods. Results The re‐intervention rate was significantly greater in the PS group than in the MS group (95% vs 4.8%, respectively, P < 0.05). EBD‐associated and postoperative complications were significantly less common in the MS group (P < 0.05). The average total preoperative medical costs were significantly lower in the MS group (PS vs MS: 528,597 vs 395,891 JPY, P = 0.004). Conclusions MS can be the first choice for EBD in patients undergoing NACRT for pancreatic head cancer. MS may be less costly overall.
- 28 February 2021
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 28 (10) , 856-863
Comparison of plastic stent versus metal stent in preoperative biliary drainage for pancreatic head cancer with neoadjuvant chemoradiotherapy
Background While neoadjuvant chemotherapy and chemoradiotherapy (NACRT) for pancreatic head cancer are effective, preoperative endoscopic biliary drainage (EBD) is necessary for managing obstructive jaundice and cholangitis during the preoperative waiting period. Nevertheless, ideal choice of stent type is unclear. We compared plastic stents (PS) and metal stents (MS) in these situations. Methods We retrospectively studied 43 patients who successfully underwent preoperative EBD prior to NACRT for pancreatic head cancer at a single institution. We divided patients into PS (n = 22) and MS (n = 21) groups. The primary outcome was the rate of re‐interventional drainage rate before surgery. Secondary outcomes were rates of EBD‐associated and postoperative complications and total costs in the pre‐ and perioperative periods. Results The re‐intervention rate was significantly greater in the PS group than in the MS group (95% vs 4.8%, respectively, P < 0.05). EBD‐associated and postoperative complications were significantly less common in the MS group (P < 0.05). The average total preoperative medical costs were significantly lower in the MS group (PS vs MS: 528,597 vs 395,891 JPY, P = 0.004). Conclusions MS can be the first choice for EBD in patients undergoing NACRT for pancreatic head cancer. MS may be less costly overall.
- 1 October 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 53 (07) , E263-E264
Endoscopic direct visualization of gallbladder polypoid lesion using peroral digital single-operator cholangioscopy
Recently, the SpyGlass (Boston Scientific, Marlborough, Massachusetts, USA) has proven effective in the diagnosis of biliary tract lesions under direct vision [1] [2] [3]. However, no reports have evaluated its usefulness in the gallbladder. Gallbladder polypoid lesions include neoplasms and a variety of benign inflammatory, granular, and hyperplastic lesions. Distinguishing between these lesions is often difficult [4], and so a novel diagnostic tool is required. This report describes the first case to our knowledge of a gallbladder polypoid lesion being successfully visualized directly using the Spyglass. An 85-year-old woman presented with acute cholangitis related to common bile duct (CBS) stones. Contrast-enhanced computed tomography (CT) showed a suspicious gallbladder tumor with enhancement, measuring 20 mm ([Fig. 1]). Endoscopic retrograde cholangiopancreatography (ERCP) was performed to remove the CBD stones and to collect bile for cytological diagnosis of the gallbladder tumor. After achieving selective bile duct cannulation, a guidewire (Visiglide2; Olympus, Tokyo, Japan) was advanced into the cystic duct and gallbladder. Cholangiography showed stones in the CBD and a tumor in the gallbladder ([Fig. 2]). With endoscopic papillary large-balloon dilation, the stones were successfully removed. Subsequently, we attempted the following approach for the gallbladder. First, bile was obtained for cytology via a catheter, and then the SpyGlass cholangioscope was inserted into the gallbladder. Because the cystic duct was straightened by the guidewire ([Fig. 3]), the cholangioscope easily passed through the cystic duct and advanced into the gallbladder ([Fig. 4]). Cholangioscopy identified a nodular elevated lesion at the gallbladder fundus, suspected of being a malignant tumor ([Fig. 5]; [Video 1]). However, targeted biopsy failed because the forceps could not pass through the curved cholangioscope. Although cytology was negative for malignancy, we recommended surgery based on CT and cholangioscopic findings, but the patient declined on the basis of advanced age. Video 1 The SpyGlass cholangioscope inserted into the gallbladder of an 85-year-old woman identified a nodular elevated tumor under direct vision. In summary, although further instrumental improvement is required, SpyGlass cholangioscopy may be an alternative option for diagnosing gallbladder lesions. Endoscopy_UCTN_Code_CCL_1AZ_2AC Publication Date: 01 October 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 October 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 53 (07) , E263-E264
Endoscopic direct visualization of gallbladder polypoid lesion using peroral digital single-operator cholangioscopy
Recently, the SpyGlass (Boston Scientific, Marlborough, Massachusetts, USA) has proven effective in the diagnosis of biliary tract lesions under direct vision [1] [2] [3]. However, no reports have evaluated its usefulness in the gallbladder. Gallbladder polypoid lesions include neoplasms and a variety of benign inflammatory, granular, and hyperplastic lesions. Distinguishing between these lesions is often difficult [4], and so a novel diagnostic tool is required. This report describes the first case to our knowledge of a gallbladder polypoid lesion being successfully visualized directly using the Spyglass. An 85-year-old woman presented with acute cholangitis related to common bile duct (CBS) stones. Contrast-enhanced computed tomography (CT) showed a suspicious gallbladder tumor with enhancement, measuring 20 mm ([Fig. 1]). Endoscopic retrograde cholangiopancreatography (ERCP) was performed to remove the CBD stones and to collect bile for cytological diagnosis of the gallbladder tumor. After achieving selective bile duct cannulation, a guidewire (Visiglide2; Olympus, Tokyo, Japan) was advanced into the cystic duct and gallbladder. Cholangiography showed stones in the CBD and a tumor in the gallbladder ([Fig. 2]). With endoscopic papillary large-balloon dilation, the stones were successfully removed. Subsequently, we attempted the following approach for the gallbladder. First, bile was obtained for cytology via a catheter, and then the SpyGlass cholangioscope was inserted into the gallbladder. Because the cystic duct was straightened by the guidewire ([Fig. 3]), the cholangioscope easily passed through the cystic duct and advanced into the gallbladder ([Fig. 4]). Cholangioscopy identified a nodular elevated lesion at the gallbladder fundus, suspected of being a malignant tumor ([Fig. 5]; [Video 1]). However, targeted biopsy failed because the forceps could not pass through the curved cholangioscope. Although cytology was negative for malignancy, we recommended surgery based on CT and cholangioscopic findings, but the patient declined on the basis of advanced age. Video 1 The SpyGlass cholangioscope inserted into the gallbladder of an 85-year-old woman identified a nodular elevated tumor under direct vision. In summary, although further instrumental improvement is required, SpyGlass cholangioscopy may be an alternative option for diagnosing gallbladder lesions. Endoscopy_UCTN_Code_CCL_1AZ_2AC Publication Date: 01 October 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB104
1173 A MULTICENTER PROSPECTIVE COHORT STUDY OF ADVERSE EVENTS ASSOCIATED WITH BILIARY ERCP
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB104
Open Access1173 A MULTICENTER PROSPECTIVE COHORT STUDY OF ADVERSE EVENTS ASSOCIATED WITH BILIARY ERCP
- Open Access
- 12 April 2018
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2018, 1-7
Long-Term Management of Recurrent Cholecystitis after Initial Conservative Treatment: Endoscopic Transpapillary Gallbladder Stenting
Background. Endoscopic transpapillary gallbladder stenting (ETGBS) is an effective procedure for treating high-risk patients with acute cholecystitis and severe comorbidities. However, the efficacy of ETGBS for recurrent cholecystitis (RC) remains unclear. This study aimed to explore its efficacy in patients with RC for whom cholecystectomy is contraindicated because of its high surgical risk.Methods. Data on 19 high-risk patients who had undergone ETGBS for RC after initial conservative therapy in our institution between June 2006 and May 2012 were retrospectively examined. The primary outcome was the clinical success rate, which was defined as no recurrences of acute cholecystitis after ETGBS until death or the end of the follow-up period. Secondary outcomes were technical success rate and adverse events (AEs).Results. The clinical success rate of ETGBS was 100%, the technical success rate 94.7%, and AE rate 5%: one patient developed procedure-related mild acute pancreatitis. The clinical courses of all patients were as follows: four died of nonbiliary disease, and the remaining 15 were subsequently treated conservatively. The median duration of follow-up was 14.95 months (range 3–42 months).Conclusions. ETGBS is an effective alternative for managing RC in high-risk patients with severe comorbidities.
- 12 April 2018
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2018, 1-7
Open AccessLong-Term Management of Recurrent Cholecystitis after Initial Conservative Treatment: Endoscopic Transpapillary Gallbladder Stenting
Background. Endoscopic transpapillary gallbladder stenting (ETGBS) is an effective procedure for treating high-risk patients with acute cholecystitis and severe comorbidities. However, the efficacy of ETGBS for recurrent cholecystitis (RC) remains unclear. This study aimed to explore its efficacy in patients with RC for whom cholecystectomy is contraindicated because of its high surgical risk.Methods. Data on 19 high-risk patients who had undergone ETGBS for RC after initial conservative therapy in our institution between June 2006 and May 2012 were retrospectively examined. The primary outcome was the clinical success rate, which was defined as no recurrences of acute cholecystitis after ETGBS until death or the end of the follow-up period. Secondary outcomes were technical success rate and adverse events (AEs).Results. The clinical success rate of ETGBS was 100%, the technical success rate 94.7%, and AE rate 5%: one patient developed procedure-related mild acute pancreatitis. The clinical courses of all patients were as follows: four died of nonbiliary disease, and the remaining 15 were subsequently treated conservatively. The median duration of follow-up was 14.95 months (range 3–42 months).Conclusions. ETGBS is an effective alternative for managing RC in high-risk patients with severe comorbidities.
- 1 January 2014
- Published by S. Karger AG in Digestive Surgery
- Vol. 31 (6) , 459-467
Factors Influencing Lymph Node Metastasis in Patients with Ampullary Adenocarcinoma
Aim: In cases of ampullary carcinoma, lymph node involvement affects the selection of treatment strategies. This study aimed to identify clinicopathologic features of ampullary carcinoma with lymph node metastases. Methods: The records of 74 consecutive patients with ampullary adenocarcinoma who underwent pancreaticoduodenectomy (PD) with regional lymph node dissection were retrospectively analyzed. Results: Twenty-two patients (30%) with lymph node metastasis had significantly worse survival after resection than those without lymph node metastasis (p = 0.017). Univariate analyses revealed that preoperative biliary drainage; elevated serum carbohydrate antigen 19-9 (≥36 U/ml); moderate-to-poor pathologic grade (G2/3); perineural, vascular, lymphatic, pancreas, and duodenal invasion; and T category were significantly associated with lymph node metastasis. In multivariate analysis, only pathologic grade (G2/3) remained significantly associated with lymph node metastasis (hazard ratio, 6.51; p = 0.035). In sub-classified analysis for T category, lymph node metastasis was found in 5 of 22 cases (22.7%) of T1 tumors. Four of five cases with lymph node metastases had a dominant G2/3 component, whereas only 2 of 17 cases without lymph node metastases had a G2/3 component in T1 tumors (p = 0.0036). Conclusions: Pathologic grade (G2/3) was significantly and independently associated with lymph node metastasis and was also a significant predictor in T1 tumor cases.
- 1 January 2014
- Published by S. Karger AG in Digestive Surgery
- Vol. 31 (6) , 459-467
Factors Influencing Lymph Node Metastasis in Patients with Ampullary Adenocarcinoma
Aim: In cases of ampullary carcinoma, lymph node involvement affects the selection of treatment strategies. This study aimed to identify clinicopathologic features of ampullary carcinoma with lymph node metastases. Methods: The records of 74 consecutive patients with ampullary adenocarcinoma who underwent pancreaticoduodenectomy (PD) with regional lymph node dissection were retrospectively analyzed. Results: Twenty-two patients (30%) with lymph node metastasis had significantly worse survival after resection than those without lymph node metastasis (p = 0.017). Univariate analyses revealed that preoperative biliary drainage; elevated serum carbohydrate antigen 19-9 (≥36 U/ml); moderate-to-poor pathologic grade (G2/3); perineural, vascular, lymphatic, pancreas, and duodenal invasion; and T category were significantly associated with lymph node metastasis. In multivariate analysis, only pathologic grade (G2/3) remained significantly associated with lymph node metastasis (hazard ratio, 6.51; p = 0.035). In sub-classified analysis for T category, lymph node metastasis was found in 5 of 22 cases (22.7%) of T1 tumors. Four of five cases with lymph node metastases had a dominant G2/3 component, whereas only 2 of 17 cases without lymph node metastases had a G2/3 component in T1 tumors (p = 0.0036). Conclusions: Pathologic grade (G2/3) was significantly and independently associated with lymph node metastasis and was also a significant predictor in T1 tumor cases.